Body site-specific and disease-specific virulome in the human microbiome

Fei Liu^{1,#}, Wanting Dong^{1,#}, Yaqiong Guo¹, Qian Xiong¹, Na Lu¹, Xiaofeng Song¹, Yong Xue², Demin Cao¹, Xinyue Fan¹, Yuan Fang¹, Zhiyuan Li¹, Jian Cao¹, Yanan Wang¹, Guowei Yang³, George F. Gao¹, Fangqing Zhao⁴, Baoli Zhu^{1,§}

¹ CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China

² College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China

³ MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 6 Rong Jing Dong Jie, Beijing 100176, P.R. China

⁴ Computational Genomics Lab, Beijing Institutes of Life Science, Chinese Academy of Sciences, 100101, Beijing, China

[#] These authors contributed equally to this work

[§] Corresponding author : Baoli Zhu (zhubaoli@im.ac.cn)

19 **Abstract**

20 Human body habitats are home to a diverse array of microbes, and within these
 21 microbial ecosystems, there are exchanges of genetic material, including virulence
 22 factors (VFs). Little is known about the diversity and abundance of VFs in different
 23 body sites and different types of diseases. We developed a virulome analysis pipeline
 24 using the species-specific sequence identity inferred from intraspecies ANI values to
 25 precisely assign reads to virulence factors. We characterized the human virulome
 26 from four body habitats, including the gut, oral cavity, skin, and vagina. Specifically,
 27 the diversity and abundance of VFs in the oral cavity were significantly higher than
 28 those in other body sites, including stool. We highlight the importance of sex-specific
 29 analysis when studying the human virulome. We analyzed data from more than 4,000
 30 samples across healthy and diseased subjects and 13 types of diseases from different
 31 metagenomic sequencing studies to characterize the disease-specific virulome.
 32 Atherosclerotic cardiovascular disease (ACVD) has a more diverse virulome than
 33 other diseases tested. Notably, many VFs, including genes for secretion systems and
 34 toxins, are more abundant in diseased subjects than in healthy controls. We present, to
 35 our knowledge, the most comprehensive healthy and diseased virulome dataset yet
 36 created.

Background

The human microbiome has been identified as an essential factor in many diseases, including obesity¹, type 2 diabetes², and cirrhosis³. Microbial metabolites and components influence the susceptibility of the host to many immune-mediated diseases and disorders⁴. Pathogen colonization is controlled by bacterial virulence and through competition with commensals⁵. Virulence factors (VFs) are typically defined as pathogen components whose loss specifically impairs virulence but not viability, including adhesins, toxins, exoenzymes, and secretion systems⁶. They are produced by pathogens that could cause diseases⁷. Although nonenterotoxigenic *B. fragilis* (NTBF) is a common component of the colon, enterotoxigenic *Bacteroides fragilis* (ETBF), which secretes *B. fragilis* toxin, could induce colonic tumors⁸. Recent studies suggest that colorectal cancer (CRC) is influenced by *pks*+ *Escherichia coli*, which contains the colibactin-producing *pks* pathogenicity island, directly impacting oncogenic mutations^{9,10}. These results highlight the need to characterize the microbiome at the strain level and the differences in VFs between healthy and diseased individuals. Moreover, we should also pay more attention to microbial communities for evaluating pathogenicity¹¹. With metagenome sequencing, we can observe all microbial genes present in a complex community¹², including VF genes. However, the extent and diagnostic implications of virulome contributions to different types of the disease remain unknown.

Currently, the virulence factor database (VFDB, <http://www.mgc.ac.cn/VFs/>) provides up-to-date knowledge of VFs from various bacterial pathogens. It serves as a comprehensive warehouse of bacterial pathogenesis knowledge, including a core dataset covering experimentally verified VFs¹³. There are also many other virulence factor databases, including Victors¹⁴, PATRIC¹⁵, and PHI-base¹⁶. Hidden Markov models¹⁷, deep convolutional neural network models¹⁸, and VFalyzer¹⁹ are used for VF classification in bacterial genomes. Whole-genome sequencing is an effective method to comprehensively identify VFs. However, the reliable and efficient characterization of VFs in the metagenome remains a challenge. Biosynthetic gene clusters could be predicted using ClusterFinder²⁰, which also yields false-positive results. We wish to apply a reasonable and stringent cutoff to the VF analysis to exclude potential false positive matches.

70

71 Here, we used species-specific sequence identity (SSI) inferred from the mean ANI
 72 values per species to precisely assign reads to virulence factors. As little is known
 73 about the abundances and diversity of VF profiles in different body habitats, we
 74 randomly selected 1,497 metagenome datasets from habitats within the human skin,
 75 oral cavity, gut, and vaginal from the Human Microbiome Project (HMP) cohort to
 76 carry out virulome analysis. We highlight the importance of sex-specific analysis
 77 when studying the human virulome. We analyzed data from 4,000 samples across
 78 healthy and diseased subjects and 13 types of diseases from different metagenomic
 79 sequencing studies to characterize the disease-specific virulome. We present, to our
 80 knowledge, the most comprehensive healthy and diseased virulome dataset yet
 81 created.

Results

Curation of the virulence factor database and establishment of the methodology for virulome classification

We curated the gene annotation of experimentally verified VFs in the VFDB, which comprises 3,228 experimentally verified gene sequences from 53 species of bacterial pathogens. *Legionella pneumophila*, *Escherichia coli*, and *Pseudomonas aeruginosa* were the top three species based on the number of their VF gene sequences in the dataset (Table S1). We manually inspected the VF gene categories. Adherence, T4SS, T3SS, invasion, toxin, and iron uptake systems were the top six categories (Table S2).

VFs are often species-specific and variably conserved between species²¹. The average nucleotide identity (ANI) was developed for bacterial species classification²². We performed intraspecies ANI analysis for each of the 53 species. Figure 1A shows that the ANI values range from 85.3% (*Pseudomonas stutzeri*) to 99.9% (*Bordetella pertussis*) for different species. We performed BLAST searches against the chromosome sequences in the complete bacterial genomes using species-specific sequence identity (SSI) thresholds and different fixed nucleotide identity cutoffs ranging from 99% to 90%. Barplot shows the number of pathogenic and nonpathogenic strains that hit at least one VF under different cutoffs (Figure 1B). In this experiment, SSI achieved almost the same high precision as 100% and 99% but at a markedly higher recall (Figure 1C). SSI performed the best in accuracy and F1 scores since it identified a high number of TPs and did not introduce many FPs.

To further confirm our method's accuracy, we compared the sequence identity of experimentally verified VFs between strains within one species to the mean ANI value in the species. Two experimentally verified VFs, namely, VFG005177 (gb|NP_664456) and VFG000959 (gb|NP_269190), were found in two strains, that is, *Streptococcus pyogenes* MGAS315 and *Streptococcus pyogenes* M1 GAS. The two genes' sequence identity was 98.9%, which is very similar to the mean ANI (98.8%) of *Streptococcus pyogenes*. In addition, VF identification that relies on fixed criteria by loose cutoffs may result in misannotations. For instance, when using an 80% identity cutoff, the experimentally verified gene *eastI* in *Escherichia coli* ONT:HND str. A16 can be found in many nonpathogenic strains, including the

115 genome of *Candidatus Sodalis pierantonius* str. SOPE (CP006568.1). However, no
116 experimentally verified virulence factor has been reported in this strain.

117

118 We identified a total of 2,893 VF gene sequences distributed across 5,250 strains
119 within 74 species using a nucleotide identity cutoff value of 100% for the BLAST
120 search against the chromosome sequences in the complete bacterial genomes. We
121 manually inspected the newly identified species and found that all of them were also
122 pathogens that could cause diseases, such as *Mycobacterium africanum*, *Klebsiella*
123 *aerogenes*, and *Pseudomonas fluorescens*. This indicated that experimentally verified
124 VFs were incomplete in the VFDB. In addition, we identified 31 prophage-
125 encoded VFs, most of which were exotoxins.

126

127 We developed a virulome analysis pipeline that uses SSI inferred from the mean ANI
128 values per species to precisely assign reads to virulence factors (Figure S1). With our
129 expanded VF database termed VFGSSI, reference sequences of VFs were carefully
130 chosen as seeds and integrated into the virulome analysis pipeline, making our
131 database more comprehensive (Figure 1D). A list of pathogens in VFGSSI that can
132 cause infections of the gastrointestinal tract or not and diseases they may cause are
133 shown in Table S3 and Table S4.

134 **Different body sites have distinct virulomes**

135 We analyzed 1,497 metagenome datasets from habitats within the human skin, oral
136 cavity, gut, and vagina from the HMP cohort (Figure 2A). The overall alpha and beta
137 diversity values for each body site were similar at the microbiome and virulome levels.
138 The Shannon diversity values of the microbiome (Figure S2A) and virulome (Figure
139 2B) in the oral cavity were significantly higher than those in other body sites.
140 Principal coordinate analysis of Bray-Curtis dissimilarities showed that the primary
141 patterns of variation in the microbiome (Figure S2B) and virulome (Figure 2C)
142 followed the major body sites (oral cavity, gut, skin, and vagina).

143

144 A unique body site virulome composition was apparent. The mean VF abundances in
145 the oral cavity were significantly higher than those in other body sites (Figure 2D). As
146 expected, vaginal sites had the lowest VF abundance. Furthermore, the mean VF
147 abundances in the samples at six major body sites are shown in Figure S3.

Specifically, the VF abundance in buccal mucosa was significantly higher than the VF abundance of other body sites. Hierarchical clustering of the prevalence of 106 VF genes (Figure 2E) and 15 VF functional categories (Figure 2F) is shown. In addition, we also performed LEfSe analysis to compare VFs (Figure S4). Specifically, in the oral cavity, the most differentially abundant VFs were capsular polysaccharide genes from antiphagocytosis.

The shared and unique VF genes among the groups were investigated. We found that 200 VFs were shared among body sites, accounting for 33.8%, 23.8%, 23.4%, and 43.8% of the total VFs identified in the gut, oral cavity, skin, and vagina, respectively (Figure S5A). Interestingly, the oral cavity and skin shared more VFs (689 types) than those shared between the gut and oral cavity (443 types) or between the gut and skin (444 types) (Figure S5B).

Interestingly, women showed a higher VF abundance in the skin and gut than men (ANOVA, $p < 0.05$, Figures S6A and S6B). Specifically, females had higher VF abundances in the anterior nares. In addition, sex-specific VFs for each body site were analyzed using LEfSe (Figures S7, S8, and S9). The availability of longitudinal samples of different body sites over two years from individuals who did not take antimicrobial drugs afforded us the ability to investigate the stability of virulomes over time (Figures S6C and S6D). There was no significant difference among samples from the same individuals except for the vagina, verifying that virulomes remained stable over a long period in different body habitats.

Different disease types have distinct virulomes

We focused on 13 types of diseases for which the virulome is largely unknown, including colorectal carcinoma (CRC), atherosclerotic cardiovascular disease (ACVD), inflammatory bowel disease (IBD), obesity, hypertension, Parkinson's disease (PD), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), gastric cancer (GC), liver cirrhosis (LC), melanoma, renal cell carcinoma (RCC), and *Mycoplasma pneumoniae* pneumonia (MPP) (Figure 3A). As the original sequencing data of healthy individuals were missing in the NSCLC, RCC, melanoma, and HCC datasets, we developed an independent healthy cohort that served as a negative

reference using the HMP gut data as mentioned above, which made intergroup comparisons possible.

First, we found that ACVD had a more diverse virulome than all the other disease types tested (P-value <0.01 for each disease, Wilcoxon rank-sum test; Figure 3B). Compared to their own healthy controls, ACVD, CRC, and LC showed a higher diversity of VFs (p <0.01, Figures S12, S13, and S14). In contrast, we did not find a more diverse virulome in obesity, IBD, PD, GC, and hypertension compared with their healthy controls.

Next, VF category prevalence was compared between diseases, and a disease-specific virulome composition was also clear (Figure 3C). We initially defined three groups for further VF category classification: high prevalence (>90%), medium prevalence (with prevalence ranging from 70% to 90%), and modest prevalence (<70%). VF categories including invasion, adherence, and iron uptake system composed the high prevalence group, characterized by consistently high prevalence in healthy and disease groups. Another six VF categories, including toxin, antiphagocytosis, autotransporter, T2SS, serum resistance, and T3SS, were the medium group members and were predominant in specific diseases. VF categories such as T6SS, Ig protease, exoenzyme, and regulation were divided into the modest group for their less predominant prevalence.

Moreover, hierarchical clustering of the mean abundance of representative VFs for each disease type is shown in Figure 3D. The top 10% (referring to the ratio of VF type numbers) of the most abundant VF genes in each type of disease, which were considered the representative VFs, are summarized in Supplementary Table S5. Specifically, compared to HMP healthy individuals, many VFs belonging to toxins were more abundant in obese individuals, while VFs encoding the iron uptake system were more abundant in hypertensive individuals. T6SS and antiphagocytosis genes were more abundant in patients with ACVD than in their healthy controls (Figure S15). Apart from invasion, adherence, and the iron uptake system, which were the universally discovered representative VF categories in those diseases, two clusters of VFs encoding secretion systems and toxins were found in ACVD and CRC patients,

213 respectively, the existence of which distinguished CRC and ACVD from other
214 diseases.

215

216 We then focused on the VF genes encoding secretion systems and toxins and their
217 pathogenic potential in ACVD and CRC. From the toxin's perspective, 12 VF genes
218 encoding colibactin in *Klebsiella pneumoniae* and two genes encoding heat-stable
219 enterotoxin 1 and L-lysine 6-monooxygenase IucD in *Escherichia coli* were
220 significantly enriched in patients with CRC, while only endotoxin genes participating
221 in LPS and capsule biosynthesis were found in patients with ACVD.

222

223 We further analyzed the average abundance of VF genes in each type of secretion
224 system separately (Figure S10). Remarkably, the type III secretion system VFs were
225 enriched in many diseases, not limited to ACVD and CRC, whereas T6SS genes were
226 more abundant in ACVD than in other diseases, implying their potential in inducing
227 ACVD.

228

229 Given that the secretion systems in bacteria mediate bacterial-bacterial or host-
230 bacterial competition by injecting diverse effectors, usually cytotoxic, into
231 prokaryotic and eukaryotic cells²³, we further analyzed the distribution of effectors in
232 different groups (Figure S11). It was evident that different sets of effector genes were
233 enriched in CRC and ACVD. As expected, many T3SS effectors were enriched in
234 both CRC and ACVD patients. Importantly, we found the enrichment of one T6SS
235 effector in the ACVD group, which supports our hypothesis that T6SS may play an
236 essential role in the pathogenicity of ACVD.

237

238 In addition to fecal samples, we analyzed the respiratory tract metagenome of
239 children, including 171 healthy children and 76 children with pneumonia. Overall, the
240 diversity of VFs was significantly lower in healthy children's respiratory tract
241 microbiomes than in children with pneumonia (Figure S16). Specifically, adhesin-
242 related genes in *Mycoplasma pneumoniae* were more abundant in children with
243 pneumonia (Figure S17). There were significant differences in respiratory microbial
244 virulomes between healthy children and children with pneumonia, probably due to the
245 differences in oropharyngeal microbial diversity²⁴.

Gut virulome comparison in diabetes mellitus (DM) and gestational diabetes (GDM) with in-house sequenced datasets

We sequenced 150 fecal DNA samples from 50 healthy Chinese adults, 50 T2D (type 2 diabetes mellitus), and 50 T2D+CVD (cardiovascular disease) patients using Illumina sequencing technology. A total of ~ 11 Gb per sample was obtained. The sequencing statistics are summarized in Table S6.

We found that patients with type 2 diabetes and cardiovascular diseases (T2D+CVD) had a more diverse virulome than patients with type 2 diabetes (T2D) and healthy controls (Figures 4A and 4B). Nonmetric multidimensional scaling (NMDS) analysis showed a clear separation between patients with T2D and healthy controls (Figure 4D). Consistent with our observation that the VF abundances were higher than those in healthy controls (Figure 4C), we found that many VFs were significantly enriched in T2D+CVD and T2D samples compared with their healthy controls (Figure 4E). The LDA scores indicated that the abundances of autotransporter-related VFs were much more enriched in T2D, while adherence and T6SS were much more enriched in T2D+CVD. The most enriched VFs in T2D and T2D+CVD were derived from *Escherichia coli* and *Klebsiella pneumoniae*. Furthermore, we compared the abundance between mobile VFs and nonmobile VFs and found that nonmobile VFs were significantly higher than mobile VFs for each group (Figure S18).

To indicate the relationship between VFs, we performed Spearman's correlation analysis between VFs. The strong ($q > 0.6$) and significant (adjusted P value < 0.05) correlations between VFs are shown in Figure 4F. Two major modules were identified within the network. One module contained VFs relating to T6SS, toxin, antiphagocytosis, adherence, and the iron uptake system. The other module contained VFs relating to T3SS, T2SS, adherence, and the iron uptake system. The VF modules are of particular interest because they represent the functional relationship between VFs. They may provide a systems perspective at the community level.

In contrast, we did not find a more diverse virulome in patients with GDM than in their healthy controls (Figure S19). DM showed a significantly diverse virulome over their healthy controls, while GDM had no statistically significant diverse virulome.

Therefore, GDM may represent transient DM, and the virulome appears to be relevant to DM pathogenesis but not GDM, although its underlying mechanisms are unknown.

Selected samples of DM from short-read results confirmed by PacBio long-read sequencing

To experimentally confirm the presence of VF genes in the human gut microbiome, we sequenced 9 fecal DNA samples from 3 healthy Chinese adults, 3 patients with T2D, and 3 patients with T2D+CVD using PacBio single-molecule real-time (SMRT) long-read sequencing technology. A total of ~ 20 Gb per sample with an average subread length of 8 kb was obtained with the PacBio Sequel II system. The sequencing statistics are summarized in Table S7. The assembly of PacBio reads yielded 37 large CCs from 1 to 5 Mb in length, considered to be bacterial chromosomes. It also generated 149 CCs (73.4 to 947.4 kb) classified as plasmids and 5 CCs (54.4 to 12.2 kb in size) as phages.

Consistent with our findings using short-read sequencing, we found that many VF genes existed in fecal sample contigs from patients. The heatmap shows the VF distribution among the 9 human gut samples using SSI (Figure 5A). The mean numbers of VFs in T2D+CVD were significantly higher than those in the other two groups. Most of the VFs were derived from *Escherichia coli* and *Klebsiella pneumoniae*, consistent with Illumina sequencing observations. VF genes in the complete genome of the *Klebsiella pneumoniae* strain KP3037 are shown in Figure 5B. Specifically, two distinct gene clusters encoding T6SS were identified and confirmed by VRprofile²⁵, a web-based tool for profiling virulence traits encoded within genome sequences of pathogenic bacteria. Mobile element-like genes, including genes involved in virulence and antibiotic resistance, were the major differences between strains.

Discussion

In this study, we conducted a comprehensive whole-body virulome analysis of the healthy human microbiota. We analyzed data from more than 4,000 samples across healthy and diseased subjects and 13 types of diseases from different metagenomic sequencing studies to characterize the disease-specific virulome. As the actual functions in the pathogenesis of predicted VF-related genes remain unclear, only experimentally verified VFs were involved in our study. We expanded the VF database termed VFGSSI and used species-specific sequence identity (SSI) inferred from the mean ANI values per species to precisely assign reads to virulence factors.

Our findings have substantially expanded our insight into the abundance and diversity of VFs in different body sites. Differences in the environmental conditions between different body habitats may be reflected in the microbiome and, consequently, the virulome. We observed a unique body-site virulome composition in this study. These findings illustrate that the healthy human microbiota, in general, beyond the gut microbiota, is a reservoir for virulence factors. This reservoir may serve as a mobile gene pool that facilitates VF transmission. The differences in eating habits, personal care, and lifestyles between men and women may lead to sex-specific differences in the composition of VF genes. Our results highlight the importance of sex-specific analysis when studying the human microbiome and virulome. New epidemiological studies are needed to evaluate the prevalence of potentially pathogenic bacteria carrying VFs in the healthy human body.

We hypothesized that the different diseases correspond to a specific virulome, especially in ACVD and CRC. Initially, the enrichment of genes encoding the type VI secretion system (T6SS) in *Klebsiella pneumoniae* was characteristic of the ACVD virulome, which was also discovered and then confirmed by PacBio's single-molecule real-time (SMRT) sequencing in an independent dataset of the Diabetic Cardiovascular Complications cohort. T6SS is widely found in gram-negative bacteria, including *Bacteroidetes* and *Proteobacteria*, and is dedicated to mediating interbacterial antagonism and niche occupancy²⁶. Recently, Verster *et al.* revealed the role of *Bacteroides fragilis* T6SS in mediating the gut microbe community²⁷. Therefore, we assumed that the existence of T6SS genes might result in the

overgrowth of *Klebsiella pneumoniae* in patients with CVD, which can explain why *Klebsiella pneumoniae* is enriched in CVD cohorts^{28,29}. In addition, endotoxin (LPS) components of *Klebsiella pneumoniae* are another signature of ACVD. As it has been reported that low-grade chronic inflammation promotes the development of CVD³⁰, the enrichment of LPS may lead to increased inflammation; therefore, it contributes to the development of ACVD.

In contrast to ACVD, patients with CRC exhibited an enrichment of genes encoding the secreted toxin colibactin (*clb*), which has been reported to be enriched in adenomatous polyposis (FAP)³¹ and leads to CRC by inducing oncogenic mutations of enterocytes³². Although previous research has focused on the ability of colibactin production in *E. coli*, in our virulome analysis, *clb* genes were annotated to the genome of *Klebsiella pneumoniae*. Since colibactin genes are not present in intestinal pathogenic *E. coli* strains but are present in *E. coli* strains isolated from human feces³³, it is reasonable that *clb* genes in *E. coli* were not found. In addition, the structure of *clb* is highly conserved among *Enterobacteriaceae*, including *Klebsiella pneumoniae*³⁴. Thus, another assumption is that the carcinogenic potential is not limited to *E. coli* but may expand to other gut bacteria with *clb* gene clusters. Due to regional, temporal, and spatial differences, it is crucial to have matched healthy controls when studying the microbiome and virulome. Together, our results suggest that VF profiles are unique to each disease and that our approach for classifying virulomes can be applied more broadly.

Understanding the impact of virulence may provide new treatment options for microbe-related diseases. The differences in VF profiles across different body sites and disease types have significant implications for verifying the virulome and finding new antibacterial treatments. This work also provides a useful reference for future virulome studies in the human microbiome.

Methods

Dataset collection

A total of 1,497 metagenome datasets from habitats within the human skin, oral cavity, gut, and vagina from the HMP cohort³⁵ were downloaded from the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA, <http://www.ncbi.nlm.nih.gov/sra>). Detailed information, including the sample ID, sequencing platform, read length, read number, data size, and accession numbers for each dataset, is shown in Supporting Information Table S8. The SRA datasets were converted to fastq using the fastq-dump module in the NCBI SRA Toolkit. We collected 2,712 samples from 13 types of diseases, including colorectal carcinoma (CRC)³⁶⁻³⁹, atherosclerotic cardiovascular disease (ACVD)⁴⁰, inflammatory bowel disease (IBD)^{3,41}, obesity⁴², hypertension⁴³, Parkinson's disease (PD)⁴⁴, non-small cell lung cancer (NSCLC)⁴⁵, hepatocellular carcinoma (HCC)⁴⁶, gastric cancer (GC)⁴⁷, cirrhosis⁴⁸, melanoma^{49,50}, renal cell carcinoma (RCC)⁴⁵ and children with *Mycoplasma pneumoniae* pneumonia (MPP)^{24,51}. In total, we analyzed more than 4,000 metagenomic samples.

DNA extraction and whole-genome sequencing.

The total genomic DNA in fecal samples was extracted using a QIAamp PowerFecal DNA Kit, following the user manual. Total DNA was eluted in 200 µL of sterile water and stored at -20°C until use. A NanoDrop was used to measure the concentration and purity of the DNAs. Library preparation was carried out following the recommended protocol from BioScientific's kit. Briefly, approximately 2 µg of DNA from each sample was used for fragmentation by Biorupter (high power: (15 s, on/90 s, off), six cycles) and end preparation by NEXT flex TM End-Repair. After PCR amplification (10 cycles), the library was purified using AMPure beads. Qubit was used to evaluate the quality and quantity of each library. For short-read sequencing of collected samples, whole-genome sequencing libraries were prepared using NexteraXT reagents (Illumina) and sequenced on an Illumina HiSeq X Ten platform. For long-read sequencing, SMRTbell libraries were sequenced on SMRT Cells (Pacific Biosciences) using magnetic bead loading and P4-C2 or P6-C4 chemistry.

Virulence factor database curation

The VFDB (Virulence Factors of Bacterial Pathogens) database⁵² is a comprehensive warehouse for deciphering bacterial pathogenesis. The VFDB (setA) core dataset comprises genes associated with experimentally verified virulence factors (VFs) for 53 bacterial species. PATRIC does not provide all the details for each VF and is not responsible for the original annotation. PHI-base focuses on plant pathogens. Although Victors includes VFs from bacteria, viruses, parasites, and fungi, VFDB focuses on human bacterial pathogens and contains more bacterial pathogens and experimentally verified VFs than Victors. This study downloaded the complete bacterial genomes from the NCBI server (accessed in Feb 2020), including 53 species of bacterial pathogens. Since the number of available genome sequences is unequal among different species, we randomly selected 100 genome sequences per species for ANI analysis and obtained averaged ANI values per species. For ANI calculations, the query organism's genome is split into 1-kbp fragments, which are then searched against a reference organism's whole genome. The average sequence identity of all matches having 60% overall sequence identity over 70% of their length is defined as the ANI between the two organisms²². To identify prophage-encoded VFs, we downloaded the complete virus genomes from the NCBI server (accessed in June 2020) and performed BLAST searches against the downloaded virus genome using the VFDB core dataset and the complete bacterial genomes (sequence identity 99%; coverage 99%).

We curated the gene annotation of experimentally verified VFs in the VFDB, which comprises 3,228 experimentally verified gene sequences from 53 species of bacterial pathogens. We identified VF gene sequences distributed across 74 species using a nucleotide identity cutoff value of 100% for the BLAST search against the chromosome sequences in the complete bacterial genomes. We performed intraspecies ANI analysis for each of the 74 species. The above-identified VF gene sequences with intraspecies ANI thresholds were used as the seeds to retrieve additional potential VF gene sequences from the complete bacterial genomes. Specifically, the complete bacterial genomes were subjected to local BLASTN against the VF gene sequences to hit potential VF sequences using species-specific sequence identity (SSI). The filtered hit sequences were extracted, and redundant sequences

were removed from the whole database. A total of 56,913 VF gene sequences with SSI (VFGSSI) serve as a reference sequence for VF gene abundance calculation, of which 6,584 were mobile VFs and 50,329 were nonmobile VFs. The mobile VF gene sequences were identified using SSI thresholds for the BLAST search against the complete bacterial genome plasmid sequences.

Metagenomic analysis

The virulome was determined first by aligning metagenomic reads to the dataset using BMap with default parameters and then processed using a custom Python script to filter the mapped reads with the specific sequence identity inferred from the mean ANI values per species. For gene abundance calculation, the read counts aligned to this gene were normalized by the gene's length and the total number of reads in the sample. We manually curated a pathogen list from a previous report⁵³ to identify pathogenic and nonpathogenic strains.

MetaPhlAn2⁵⁴ was used to perform taxonomic classification and profiling by mapping metagenomic reads against a library of clade-specific markers. PacBio sequencing reads were assembled by Canu⁵⁵. VirSorter⁵⁶ was used for the classification of CCs as phages. Categories 1, 2, 4, and 5 were considered phages, while categories 3 and 6 were excluded because they included false positives. PlasFlow⁵⁷ was used to identify plasmid-like contigs. Gene identification was performed on assembled sequences using MetaGeneMark⁵⁸. The number of unique and shared VFs was calculated for the compared sample types, and Venn diagrams were drawn in Python using the Venn and matplotlib-venn packages.

Statistical analysis

Principal coordinate analysis (PCoA) and nonmetric multidimensional scaling (NMDS) were performed to evaluate the differences in VF profiles among samples based on the Bray–Curtis distance of VF relative abundance. Permutational multivariate analysis of variance (PERMANOVA) between different groups was performed with adonis in vegan with a similarity index using 9999 permutations. LEfSe⁵⁹ analysis was used to identify discriminative VF types between groups. Diversity and heatmaps were prepared in R with vegan and ggplot2 packages.

Competing interests

The authors declare that they have no competing interests.

Author contributions

FL and BLZ conceived and designed the study; FL, WTD, YQG, XFS, YX, DMC, XYF, YF, QX, NL, ZYL, JC, YNW collected and characterized the data; FL performed the data analysis; FL and WTD drafted the manuscript. All of the authors read and approved the final manuscript.

Abbreviations

VFs: virulence factors; **ACVD**: atherosclerotic cardiovascular disease; **IBD**: inflammatory bowel disease; **CRC**: colorectal carcinoma; **NSCLC**: non-small cell lung cancer; **HCC**: hepatocellular carcinoma; **GC**: gastric cancer; **PD**: Parkinson's disease; **RCC**: renal cell carcinoma; **PCoA**: principal coordinate analysis; **NMDS**: nonmetric multidimensional scaling.

Acknowledgements

This work was supported in part by the Strategic Priority Research Program of The Chinese Academy of Sciences (XDB29020203) and the National Key R&D Program of China (2018YFC1603903 and 2018YFC1603803-2).

References

- 1 Turnbaugh, P. J. *et al.* A core gut microbiome in obese and lean twins. *Nature* **457**, 480-484, doi:10.1038/nature07540 (2009).
- 2 Qin, J. *et al.* A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* **490**, 55-60, doi:10.1038/nature11450 (2012).
- 3 Nielsen, H. B. *et al.* Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. *Nat Biotechnol* **32**, 822-828, doi:10.1038/nbt.2939 (2014).
- 4 Rooks, M. G. & Garrett, W. S. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol* **16**, 341-352, doi:10.1038/nri.2016.42 (2016).
- 5 Kamada, N. *et al.* Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. *Science* **336**, 1325-1329, doi:10.1126/science.1222195 (2012).
- 6 Brown, S. P., Cornforth, D. M. & Mideo, N. Evolution of virulence in opportunistic pathogens: generalism, plasticity, and control. *Trends Microbiol* **20**, 336-342, doi:10.1016/j.tim.2012.04.005 (2012).

- 495 7 Falkow, S. Molecular Koch's postulates applied to bacterial pathogenicity--a
496 personal recollection 15 years later. *Nature reviews. Microbiology* **2**, 67-72
497 (2004).
- 498 8 Wu, S. *et al.* A human colonic commensal promotes colon tumorigenesis via
499 activation of T helper type 17 T cell responses. *Nat Med* **15**, 1016-1022,
500 doi:10.1038/nm.2015 (2009).
- 501 9 Pleguezuelos-Manzano, C. *et al.* Mutational signature in colorectal cancer
502 caused by genotoxic pks E. coli. *Nature* **580**, 269-273, doi:10.1038/s41586-
503 020-2080-8 (2020).
- 504 10 Arthur, J. C. *et al.* Intestinal inflammation targets cancer-inducing activity of
505 the microbiota. *Science* **338**, 120-123, doi:10.1126/science.1224820 (2012).
- 506 11 Byrd, A. L. & Segre, J. A. Infectious disease. Adapting Koch's postulates.
507 *Science* **351**, 224-226, doi:10.1126/science.aad6753 (2016).
- 508 12 Qin, J. *et al.* A human gut microbial gene catalogue established by
509 metagenomic sequencing. *Nature* **464**, 59-65, doi:10.1038/nature08821
510 (2010).
- 511 13 Chen, L. *et al.* VFDB: a reference database for bacterial virulence factors.
512 *Nucleic acids research* **33**, D325-328, doi:10.1093/nar/gki008 (2005).
- 513 14 Sayers, S. *et al.* Victors: a web-based knowledge base of virulence factors in
514 human and animal pathogens. *Nucleic acids research* **47**, D693-D700,
515 doi:10.1093/nar/gky999 (2019).
- 516 15 Wattam, A. R. *et al.* Improvements to PATRIC, the all-bacterial
517 Bioinformatics Database and Analysis Resource Center. *Nucleic Acids Res* **45**,
518 D535-D542, doi:10.1093/nar/gkw1017 (2017).
- 519 16 Urban, M. *et al.* PHI-base: the pathogen-host interactions database. *Nucleic*
520 *Acids Res* **48**, D613-D620, doi:10.1093/nar/gkz904 (2020).
- 521 17 Martínez-García, P. M., Ramos, C. & Rodríguez-Palenzuela, P. T346Hunter: a
522 novel web-based tool for the prediction of type III, type IV and type VI
523 secretion systems in bacterial genomes. *PloS one* **10**, e0119317,
524 doi:10.1371/journal.pone.0119317 (2015).
- 525 18 Zheng, D., Pang, G., Liu, B., Chen, L. & Yang, J. Learning transferable deep
526 convolutional neural networks for the classification of bacterial virulence
527 factors. *Bioinformatics* (Oxford, England),
528 doi:10.1093/bioinformatics/btaa230 (2020).
- 529 19 Liu, B., Zheng, D., Jin, Q., Chen, L. & Yang, J. VFDB 2019: a comparative
530 pathogenomic platform with an interactive web interface. *Nucleic acids*
531 *research* **47**, D687-D692, doi:10.1093/nar/gky1080 (2019).
- 532 20 Cimermancic, P. *et al.* Insights into secondary metabolism from a global
533 analysis of prokaryotic biosynthetic gene clusters. *Cell* **158**, 412-421,
534 doi:10.1016/j.cell.2014.06.034 (2014).
- 535 21 Theuretzbacher, U. & Piddock, L. J. V. Non-traditional Antibacterial
536 Therapeutic Options and Challenges. *Cell Host Microbe* **26**, 61-72,
537 doi:10.1016/j.chom.2019.06.004 (2019).
- 538 22 Goris, J. *et al.* DNA-DNA hybridization values and their relationship to
539 whole-genome sequence similarities. *International journal of systematic and*
540 *evolutionary microbiology* **57**, 81-91, doi:10.1099/ijs.0.64483-0 (2007).
- 541 23 Galan, J. E. & Waksman, G. Protein-Injection Machines in Bacteria. *Cell* **172**,
542 1306-1318, doi:10.1016/j.cell.2018.01.034 (2018).

543 24 Dai, W. *et al.* An integrated respiratory microbial gene catalogue to better
544 understand the microbial aetiology of *Mycoplasma pneumoniae* pneumonia.
545 *GigaScience* **8**, doi:10.1093/gigascience/giz093 (2019).
546 25 Li, J. *et al.* VRprofile: gene-cluster-detection-based profiling of virulence and
547 antibiotic resistance traits encoded within genome sequences of pathogenic
548 bacteria. *Brief Bioinform* **19**, 566-574, doi:10.1093/bib/bbw141 (2018).
549 26 Russell, A. B. *et al.* A type VI secretion-related pathway in *Bacteroidetes*
550 mediates interbacterial antagonism. *Cell Host Microbe* **16**, 227-236,
551 doi:10.1016/j.chom.2014.07.007 (2014).
552 27 Verster, A. J. *et al.* The Landscape of Type VI Secretion across Human Gut
553 Microbiomes Reveals Its Role in Community Composition. *Cell Host Microbe*
554 **22**, 411-419 e414, doi:10.1016/j.chom.2017.08.010 (2017).
555 28 Liu, H. *et al.* Alterations in the gut microbiome and metabolism with coronary
556 artery disease severity. *Microbiome* **7**, 68, doi:10.1186/s40168-019-0683-9
557 (2019).
558 29 Ott, S. J. *et al.* Detection of diverse bacterial signatures in atherosclerotic
559 lesions of patients with coronary heart disease. *Circulation* **113**, 929-937,
560 doi:10.1161/CIRCULATIONAHA.105.579979 (2006).
561 30 Livshits, G. & Kalinkovich, A. Inflammaging as a common ground for the
562 development and maintenance of sarcopenia, obesity, cardiomyopathy and
563 dysbiosis. *Ageing Res Rev* **56**, 100980, doi:10.1016/j.arr.2019.100980 (2019).
564 31 Dejea, C. M. *et al.* Patients with familial adenomatous polyposis harbor
565 colonic biofilms containing tumorigenic bacteria. *Science* **359**, 592-597,
566 doi:10.1126/science.aah3648 (2018).
567 32 Pleguezuelos-Manzano, C. *et al.* Mutational signature in colorectal cancer
568 caused by genotoxic pks(+) *E. coli*. *Nature* **580**, 269-273, doi:10.1038/s41586-
569 020-2080-8 (2020).
570 33 Nougayrede, J. P. *et al.* *Escherichia coli* induces DNA double-strand breaks in
571 eukaryotic cells. *Science* **313**, 848-851, doi:10.1126/science.1127059 (2006).
572 34 Putze, J. *et al.* Genetic structure and distribution of the colibactin genomic
573 island among members of the family Enterobacteriaceae. *Infect Immun* **77**,
574 4696-4703, doi:10.1128/IAI.00522-09 (2009).
575 35 Lloyd-Price, J. *et al.* Strains, functions and dynamics in the expanded Human
576 Microbiome Project. *Nature* **550**, 61-66, doi:10.1038/nature23889 (2017).
577 36 Feng, Q. *et al.* Gut microbiome development along the colorectal adenoma-
578 carcinoma sequence. *Nat Commun* **6**, 6528, doi:10.1038/ncomms7528 (2015).
579 37 Vogtmann, E. *et al.* Colorectal Cancer and the Human Gut Microbiome:
580 Reproducibility with Whole-Genome Shotgun Sequencing. *PLoS ONE* **11**,
581 e0155362, doi:10.1371/journal.pone.0155362 (2016).
582 38 Wirbel, J. *et al.* Meta-analysis of fecal metagenomes reveals global microbial
583 signatures that are specific for colorectal cancer. *Nat Med* **25**, 679-689,
584 doi:10.1038/s41591-019-0406-6 (2019).
585 39 Yu, J. *et al.* Metagenomic analysis of faecal microbiome as a tool towards
586 targeted non-invasive biomarkers for colorectal cancer. *Gut* **66**, 70-78,
587 doi:10.1136/gutjnl-2015-309800 (2017).
588 40 Jie, Z. *et al.* The gut microbiome in atherosclerotic cardiovascular disease. *Nat*
589 *Commun* **8**, 845, doi:10.1038/s41467-017-00900-1 (2017).
590 41 Franzosa, E. A. *et al.* Gut microbiome structure and metabolic activity in
591 inflammatory bowel disease. *Nat Microbiol* **4**, 293-305, doi:10.1038/s41564-
592 018-0306-4 (2019).

593 42 Le Chatelier, E. *et al.* Richness of human gut microbiome correlates with
594 metabolic markers. *Nature* **500**, 541-546, doi:10.1038/nature12506 (2013).
595 43 Li, J. *et al.* Gut microbiota dysbiosis contributes to the development of
596 hypertension. *Microbiome* **5**, 14, doi:10.1186/s40168-016-0222-x (2017).
597 44 Bedarf, J. R. *et al.* Functional implications of microbial and viral gut
598 metagenome changes in early stage L-DOPA-naïve Parkinson's disease
599 patients. *Genome Med* **9**, 39, doi:10.1186/s13073-017-0428-y (2017).
600 45 Routy, B. *et al.* Gut microbiome influences efficacy of PD-1-based
601 immunotherapy against epithelial tumors. *Science* **359**, 91-97,
602 doi:10.1126/science.aan3706 (2018).
603 46 Zheng, Y. *et al.* Gut microbiome affects the response to anti-PD-1
604 immunotherapy in patients with hepatocellular carcinoma. *J Immunother*
605 *Cancer* **7**, 193, doi:10.1186/s40425-019-0650-9 (2019).
606 47 Erawijantari, P. P. *et al.* Influence of gastrectomy for gastric cancer treatment
607 on faecal microbiome and metabolome profiles. *Gut* **69**, 1404-1415,
608 doi:10.1136/gutjnl-2019-319188 (2020).
609 48 Qin, N. *et al.* Alterations of the human gut microbiome in liver cirrhosis.
610 *Nature* **513**, 59-64, doi:10.1038/nature13568 (2014).
611 49 Matson, V. *et al.* The commensal microbiome is associated with anti-PD-1
612 efficacy in metastatic melanoma patients. *Science* **359**, 104-108,
613 doi:10.1126/science.aao3290 (2018).
614 50 Frankel, A. E. *et al.* Metagenomic Shotgun Sequencing and Unbiased
615 Metabolomic Profiling Identify Specific Human Gut Microbiota and
616 Metabolites Associated with Immune Checkpoint Therapy Efficacy in
617 Melanoma Patients. *Neoplasia* **19**, 848-855, doi:10.1016/j.neo.2017.08.004
618 (2017).
619 51 Liu, F., Wang, Y., Gao, G. F. & Zhu, B. Metagenomic analysis reveals the
620 abundance and diversity of ARGs in children's respiratory tract microbiomes.
621 *The Journal of infection* **80**, 232-254, doi:10.1016/j.jinf.2019.11.002 (2020).
622 52 Liu, B., Zheng, D., Jin, Q., Chen, L. & Yang, J. VFDB 2019: a comparative
623 pathogenomic platform with an interactive web interface. *Nucleic acids*
624 *research* **47**, D687-D692, doi:10.1093/nar/gky1080 (2019).
625 53 Blauwkamp, T. A. *et al.* Analytical and clinical validation of a microbial cell-
626 free DNA sequencing test for infectious disease. *Nat Microbiol* **4**, 663-674,
627 doi:10.1038/s41564-018-0349-6 (2019).
628 54 Truong, D. T. *et al.* MetaPhlAn2 for enhanced metagenomic taxonomic
629 profiling. *Nature methods* **12**, 902-903, doi:10.1038/nmeth.3589 (2015).
630 55 Koren, S. *et al.* Canu: scalable and accurate long-read assembly via adaptive
631 k-mer weighting and repeat separation. *Genome research* **27**, 722-736,
632 doi:10.1101/gr.215087.116 (2017).
633 56 Roux, S., Enault, F., Hurwitz, B. L. & Sullivan, M. B. VirSorter: mining viral
634 signal from microbial genomic data. *PeerJ* **3**, e985, doi:10.7717/peerj.985
635 (2015).
636 57 Krawczyk, P. S., Lipinski, L. & Dziembowski, A. PlasFlow: predicting
637 plasmid sequences in metagenomic data using genome signatures. *Nucleic*
638 *acids research* **46**, e35, doi:10.1093/nar/gkx1321 (2018).
639 58 Zhu, W., Lomsadze, A. & Borodovsky, M. Ab initio gene identification in
640 metagenomic sequences. *Nucleic acids research* **38**, e132,
641 doi:10.1093/nar/gkq275 (2010).

642 59 Segata, N. *et al.* Metagenomic biomarker discovery and explanation. *Genome*
643 *biology* **12**, R60, doi:10.1186/gb-2011-12-6-r60 (2011).
644

Figures

Figure 1. Comparison of the intraspecies whole-genome average nucleotide identity and accuracy of different thresholds for VF identification. (A) Barplot depicting the average nucleotide identity values of the 53 species of bacterial pathogens. (B) Barplot showing the number of pathogenic and nonpathogenic strains that hit at least one VF under different cutoffs. (C) Precision and recall graph for pathogenic and nonpathogenic strain identification under different cutoffs. We performed intraspecies ANI analysis for each of the 53 species. Figure 1A shows that the ANI values range from 85.3% (*Pseudomonas stutzeri*) to 99.9% (*Bordetella pertussis*) for different species. We performed BLAST searches against the chromosome sequences in the complete bacterial genomes using species-specific sequence identity (SSI) thresholds and different nucleotide identity cutoffs ranging from 99% to 90%. In this experiment, SSI achieved almost the same high precision as 100% and 99% but at a markedly higher recall (Figure 1C). SSI performed the best in accuracy and F1 scores since it identified high TPs and did not introduce many FPs. (D) Schematic representation of the curation of the VF dataset.

Figure 2. Different body sites have a distinct virulome. (A) Number of samples analyzed in the study. (B) Boxplot of the Shannon diversity indexes of all samples from different body sites based on VF abundance profiles. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, Wilcoxon rank-sum test. (C) Principal coordinate analysis of Bray-Curtis dissimilarities showing the virulome. The first principal coordinate is shown by the x-axis, and the second principal coordinate is shown by the y-axis. (D) Comparison of the mean VF abundance. The centerline represents the median for each boxplot, and the boxes correspond to the 25th and 75th percentiles; all data points are shown. Hierarchical clustering of the prevalence of 106 VF genes (E) and 15 VF functional categories (F) that were hit in one of the body sites and are present in 20% or more of the samples in at least one body site. For the virulome analysis, the mean VF abundances in oral samples were significantly higher than those in other body sites. As expected, the vagina had the lowest total VF abundance. Additionally, the Shannon diversity values of VFs in the oral cavity and gut were significantly higher than those of VFs in other body sites.

Figure 3. Different disease types have a distinct virulome. (A) Number of samples analyzed in the study. Dashes indicate data not available. ACVD, atherosclerotic cardiovascular disease; IBD, inflammatory bowel disease; CRC,

679 colorectal carcinoma; NSCLC, non-small cell lung cancer; HCC,
680 hepatocellular carcinoma; GC, gastric cancer; PD, Parkinson's disease; RCC,
681 renal cell carcinoma. (B) Boxplot of the Shannon diversity indexes of all samples
682 from different types of diseases based on VF abundance profiles. (C) Hierarchical
683 clustering of the prevalence of VF categories that were hits in one of the disease
684 types and were present in 20% or more of the samples in at least one of the disease
685 types. (D) Hierarchical clustering of the mean abundance of representative VFs for
686 each type of disease. The top 10% (referring to the ratio of VF type numbers) of the
687 most abundant VF types in each type of disease were considered the representative
688 VFs.

689 **Figure 4. Patients with type 2 diabetes with cardiovascular diseases**
690 **(T2D+CVD) had a more diverse virulome.** (A) Boxplot of the number of VF genes
691 present in each sample. (B) Boxplot of the Shannon diversity indexes of all samples
692 based on the virulome. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, Wilcoxon
693 rank-sum test. (C) Comparison of the mean VF abundance. For each boxplot, the
694 centerline represents the median, and the boxes correspond to the 25th and 75th
695 percentiles; all data points are shown. (D) NMDS of Bray-Curtis dissimilarities
696 showing the virulome. Bray-Curtis dissimilarities were calculated from the relative VF
697 abundance profiles. The x-axis shows the first principal coordinate, and the y-axis
698 shows the second principal coordinate. (E) Histogram of the LDA scores (log10)
699 computed for VFs with differential abundance in the healthy, T2D, and T2D+CVD
700 subjects. The LDA scores indicated that the abundances of autotransporter-related
701 VFs were much more enriched in T2D, while adherence and T6SS were much more
702 enriched in T2D+CVD. Most of the enriched VFs in T2D and T2D+CVD were derived
703 from *Escherichia coli* and *Klebsiella pneumoniae*. (F) Network analysis
704 demonstrating the co-occurrence patterns between VFs. The nodes are colored
705 according to the VF genes, with each node representing a VF subtype. The size of
706 each node is proportional to its number of connections. An edge is a strong ($q > 0.6$)
707 and significant (P -value < 0.01) connection between nodes.

708 **Figure 5. PacBio long-read sequencing confirmation of VF genes that exist in**
709 **the contigs of fecal samples.** (A) Heatmap shows the VF distribution among the 9
710 human gut samples using SSI. The mean numbers of VFs in T2D+CVD were
711 significantly higher than those in the other two groups. Most of the VFs were derived
712 from *Escherichia coli* and *Klebsiella pneumoniae*, consistent with Illumina sequencing
713 observations. (B) BLAST ring image of the two complete genomes of *Klebsiella*

714 *pneumoniae*. The *Klebsiella pneumoniae* strain KP3037 was used as the reference
715 in the outermost ring. The two innermost rings represent the GC content of that area
716 and the GC skew, respectively. The saturation of the color in these rings indicates
717 identity by BLAST hit.

718 Additional Files

719 Additional file 1

720 **Figure S1. Schematic representation of the virulome analysis pipeline.** We
 721 curated the gene annotation of experimentally verified VFs in the VFDB, which
 722 comprises 3,228 experimentally verified gene sequences from 53 species of bacterial
 723 pathogens. We identified VF gene sequences distributed across 74 species using a
 724 nucleotide identity cutoff value of 100% for the BLAST search against the
 725 chromosome sequences in the complete bacterial genomes. We downloaded the
 726 complete bacterial genomes from the NCBI server (accessed on Feb 2020), including
 727 74 species of bacterial pathogens. We performed intraspecies ANI analysis for each
 728 of the 74 species. The above-identified VF gene sequences with intraspecies ANI
 729 thresholds were used as the seeds to retrieve additional potential VF gene
 730 sequences from the complete bacterial genomes. Specifically, the complete bacterial
 731 genomes were subjected to local BLASTN against the VF gene sequences to hit
 732 potential VF sequences using species-specific sequence identity (SSI). The filtered
 733 hit sequences were extracted, and redundant sequences were removed from the
 734 whole database. The final VF gene sequences with SSI serve as a reference
 735 sequence for VF gene abundance calculation.

736 **Figure S2. Different body sites have distinct microbiomes.** (A) Boxplot of the
 737 Shannon diversity indexes of all samples from different body sites based
 738 on relative species abundance profiles. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p <$
 739 0.0001 , Wilcoxon rank-sum test. (B) Principal coordinate analysis of Bray-Curtis
 740 dissimilarities showing the microbiome. Bray-Curtis dissimilarities were calculated
 741 from the relative species abundance profiles. The x-axis shows the first principal
 742 coordinate, and the y-axis shows the second principal coordinate.

743 **Figure S3. Comparison of mean VF abundance in the samples at six major**
 744 **body sites.** For each boxplot, the centerline represents the median, and the boxes
 745 correspond to the 25th and 75th percentiles; all data points are shown.

746 **Figure S4. Histogram of the LDA scores (log10) computed for VFs with**
 747 **differential abundance in different body sites.**

748 **Figure S5. Venn diagram showing the number of shared and unique VF genes**
 749 **among different body sites.** (A) Venn diagram of the four body sites. (B) Venn

750 diagram of each pair of body sites. The number of shared and unique VF genes is
751 shown. The shared and unique VF genes among the groups were investigated. We
752 found that a total of 200 VF genes were shared among body sites. Interestingly, the
753 oral cavity and skin shared more VFs (689 types) than those shared between the gut
754 and oral cavity (443 types) or between the gut and skin (444 types).

755 **Figure S6. VF gene profiles were sex-specific and relatively stable over time.**

756 Comparison of the total VF abundance between males and females in four major
757 body habitats (A) and six major body sites (B). Comparison of the total VF
758 abundance among samples from the same individuals over time in four major body
759 habitats (C) and six major body sites (D). In the boxplots, the upper hinge represents
760 the 75% quantile, the lower hinge represents the 25% quantile, and the centerline
761 represents the median. Compared to men, women showed a higher VF abundance in
762 the skin and gut (ANOVA, $p < 0.05$). Specifically, females had higher VF abundance
763 in the anterior nares. The availability of longitudinal samples of different body sites
764 over two years from individuals who did not take antimicrobial drugs afforded us the
765 ability to investigate the stability of virulomes over time. There was no significant
766 difference among samples from the same individuals except for the vagina, verifying
767 that virulomes remained stable over a long period in different body habitats.

768 **Figure S7. Histogram of the LDA scores (log10) computed for VFs with**
769 **differential abundance between males and females in the gut.**

770 **Figure S8. Histogram of the LDA scores (log10) computed for VFs with**
771 **differential abundance between males and females in the oral cavity.**

772 **Figure S9. Histogram of the LDA scores (log10) computed for VFs with**
773 **differential abundance between males and females in the skin.**

774 **Figure S10. Hierarchical clustering of the mean abundance of VFs encoding**
775 **secretion systems for each type of disease.**

776 **Figure S11. Hierarchical clustering of the mean abundance of VFs encoding**
777 **effectors of secretion systems for each type of disease.**

778 **Figure S12. Richness, Simpson, Shannon, and evenness diversity of VFs in**
779 **ACVD samples.**

780 **Figure S13. Richness, Simpson, Shannon, and evenness diversity of VFs in**
781 **CRC samples.**

782 **Figure S14. Richness, Simpson, Shannon, and evenness diversity of VFs in LC**
783 **samples.**

784 **Figure S15. Histogram of the LDA scores (log10) computed for VFs with**
785 **differential abundance in ACVD samples.**

786 **Figure S16. Richness, Simpson, Shannon, and evenness diversity of VFs in the**
787 **children's respiratory tract metagenome samples.**

788 **Figure S17. Histogram of the LDA scores (log10) computed for VFs with**
789 **differential abundance in the children's respiratory tract metagenome samples.**

790 **Figure S18. Comparison of mobile and intrinsic VF abundance. "Intrinsic VFs"**
791 **are VFs located only on the bacterial chromosome. "Mobile VFs" are VFs**
792 **located on plasmids. Each dot represents a metagenome sample. For each boxplot,**
793 **the centerline represents the median, and the boxes correspond to the 25th and 75th**
794 **percentiles; all data points are shown.**

795 **Figure S19. Richness, Simpson, Shannon, and evenness diversity of VFs in**
796 **GDM samples.**

797 **Additional file 2**

798 **Table S1. The number of VF gene sequences from each species in the dataset.**

799 **Table S2. Distribution of the number of sequences in the VF categories in the**
800 **dataset.**

801 **Table S3. List of pathogens that can cause infections of the gastrointestinal**
802 **tract and the diseases they cause.**

803 **Table S4. List of pathogens that cannot cause infections of the gastrointestinal**
804 **tract and the diseases they cause.**

805 **Table S5. The top 10% (referring to the ratio of VF type numbers) of the most**
806 **abundant VF types in each type of disease, which were considered the**
807 **representative VFs, are summarized.**

808 **Table S6. The Illumina short-read sequencing statistics.**

809 **Table S7. The PacBio long-read sequencing statistics.**

810 **Table S8. Detailed information on 1,497 metagenome datasets from habitats**
811 **within the human skin, oral cavity, gut, and vagina from the HMP cohort is**
812 **summarized.**

A

B

C

D

A

Body site	Gender	# samples
Gut	Female	124
	Male	147
Oral	Female	383
	Male	429
Skin	Female	81
	Male	132
Vaginal	Female	115
Total	1497	

B

C

D

E

F

A

Type of Disease	Normal: # samples (# centers)	Disease: # samples (# centers)
IBD	127 (2)	312 (2)
CRC	229 (4)	232 (4)
ACVD	171	214
Obesity	123	169
NSCLC	—	118
Cirrhosis	123	114
RCC	—	101
Hypertension	41	98
Melanoma	—	79 (2)
Pneumonia	171	76
GC	50	56
HCC	—	50
PD	27	31
Total	2712	

B

C

D

A

B